Extended- and continuous-cycle oral contraceptives

Pharmacotherapy

Volumn 28, Issue 8, 2008, Pages 1033-1040

  Shrader, Sarah P ^a   Dickerson, Lori M ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

24 4 regimen; 84 7 regimen; Continuous cycle; Extended cycle; Hormonal contraceptive; Oral contraceptive

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; ORAL CONTRACEPTIVE AGENT; SEASONIQUE; YAZ;

AMENORRHEA; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE FERTILITY; FOOD AND DRUG ADMINISTRATION; GALLBLADDER DISEASE; HEADACHE; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; MENSTRUAL CYCLE; MENSTRUATION; NAUSEA; ORAL CONTRACEPTION; PATIENT COUNSELING; PILL; PREGNANCY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SPOTTING; SYMPTOMATOLOGY; VAGINA RING; VENOUS THROMBOEMBOLISM; WEIGHT CHANGE; WITHDRAWAL BLEEDING;

ATTITUDE OF HEALTH PERSONNEL; CONTRACEPTION; CONTRACEPTIVES, ORAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUAL CYCLE;

EID: 48249137337     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.8.1033     Document Type: Review

References (37)

1. Black A, Kives S, Leboeuf M, et al. Canadian consensus guideline on continuous and extended hormonal contraception, 2007. SOGC clinical practice guideline, No. 195, July 2007. J Obstet Gynaecol Can 2007;195:S1-32.
2. Hatcher RA, Zieman M, Cwiak C, et al. A pocket guide to managing contraception. Tiger, GA: Bridging the Gap Foundation, 2005.
3. Duramed Pharmaceuticals. The truth about fewer periods. Available from http://www.fewerperiods.com. Accessed September 7, 2007.
4. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000;355:922-4.
5. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004;69:37-42.
6. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception: an international study on acceptability. Contraception 2003;67:1-8.
7. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004;70:359-63.
8. Sulak PJ, Buckley T, Kuehl TJ. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception 2006;73:41-5.
9. Bayer Pharmaceuticals. Yaz (drospirenone-ethinyl estradiol) package insert. Wayne, NJ; 2007.
10. Warner Chilcott. Loestrin 24 Fe (norethindrone acetate-ethinyl estradiol) package insert. Rockaway, NJ; 2006.
11. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception 1999;60:321-9.
12. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin 24 Fe). Contraception 2007;75:16-22.
13. Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Kowal D, eds. Contraceptive technology, 18th ed. New York: Ardent Media, Inc., 2004.
14. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
15. Anderson FD, Hait H, for the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96.
16. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006;195:92-6.
17. Killick SR, Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 1998;179:S18-24.
18. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-34.
19. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005;3:CD004695.
20. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101:653-61.
21. Archer DF, Jensen JT, Johnson JV, Borisute H, Grub GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439-45.
22. Organon Pharmaceuticals. NuvaRing (etonogestrel-ethinyl estradiol) package insert. Roseland, NJ; 2005.
23. Ortho-McNeil Pharmaceuticals. Ortho Evra (norelgestromin-ethinyl estradiol) package insert. Raritan, NJ; 2006.
24. Oddsson K, Leifles-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 mcg ethinyl estradiol and 150 mcg levonorgestrel: a randomized trial. Hum Reprod 2005;20:557-62.
25. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555-63.
26. Miller L, Verhoeven CH, in't Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol 2005;106:473-82.
27. Stewart FH, Kaunitz AM, LaGuardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of a transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005;105:1389-96.
28. Jick SS, Kaye JA, Russman S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg ethinyl estradiol. Contraception 2006;73:223-8.
29. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46.
30. Duramed Pharmaceuticals. Seasonale (levonorgestrel-ethinyl estradiol) package insert. Pomona, NY; 2003.
31. Duramed Pharmaceuticals. Seasonique (levonorgestrel-ethinyl estradiol) package insert. Pomona, NY; 2006.
32. Wyeth Pharmaceuticals. Lybrel (levonorgestrel-ethinyl estradiol) package insert. Philadelphia, PA; 2007.
33. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin North Am 2007;34:43-55.
34. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005;71:55-9.
35. Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg. Contraception 2007;75:23-6.
36. Davis AR, Kroll R, Sokes B, Haudiquet V, Constantine G, Grubb G. Return to menses after continuous use of a low-dose oral contraceptive [abstract]. Obstet Gynecol 2006;107:3S.
37. Drugstore.com. Prescription price checker. Available from http://www.drugstore.com. Accessed September 7, 2007.